New combo aims to shrink tumors before lung cancer surgery
NCT ID NCT07354061
Summary
This study is testing if a targeted drug called ensartinib, when combined with standard chemotherapy, can effectively shrink tumors before surgery for patients with a specific type of lung cancer (ALK-positive NSCLC). The main goal is to see if this pre-surgery treatment can completely eliminate cancer cells in the removed tumor. All 20 participants will receive the drug combination and be closely monitored for safety and long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.